在儿童中成功使用瑞桑基祖马布治疗皮病Rubra Pilaris
Marta Kołt-Kamińska1, Antonina Osińska2, Ewa Kaznowska3
1Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University, Szopena 2, 35-055, Rzeszów, Poland.
Dermatology and therapy
|September 13, 2023
概括
皮疹 (Pityriasis rubra pilaris,简称PRP) 是一种罕见的皮肤疾病. 作为一种IL-23抑制剂的瑞桑基祖马布 (risankizumab) 有效且安全地治疗了三名患有严重PRP的儿科患者,这些患者对其他疗法没有反应.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
背景情况:
- 皮病 (Pityriasis rubra pilaris,简称PRP) 是一种罕见的炎症性皮肤病,其病因不明.
- PRP表现为毛囊皮质增生症和斑,这给治疗带来了挑战,特别是在儿童中.
- IL-23/Th17轴与PRP有关,这表明它是一个治疗点.
研究的目的:
- 评估瑞桑基祖马布在患有严重皮病的儿科患者的疗效和安全性.
- 评估Risankizumab作为对PRP病例的治疗选择,这些病例对传统疗法具有耐药性.
主要方法:
- 三名患有严重PRP的儿科患者的病例系列.
- 使用不同剂量 (75毫克或150毫克) 的瑞桑基祖马布 (IL-23抑制剂) 治疗.
- 基于皮肤病变清除和不良事件的治疗反应的评估.
主要成果:
- 两名患者在第4周获得了近乎完全的清除,服用一次75毫克的瑞桑基祖马布剂量.
- 第三名患者在第二次150毫克剂量后获得了清晰的皮肤.
- 所有患者都能很好地耐受瑞桑基祖马布,在观察期间没有报告任何不良反应.
结论:
- 瑞桑基祖马布在治疗儿科皮病rubra pilaris时表现出显著的疗效和良好的安全性.
- 用瑞桑基祖马布阻断IL-23代表了严重儿科PRP的有希望的治疗策略.
- 需要进一步的研究来证实这些发现在更大的儿科队伍中.
相关概念视频
Acne Infection
Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
Respiratory Syncytial Virus Disease
Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...


